RecruitingNot Applicable

Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With Vimseltinib

United States100 participantsStarted 2025-09-03

Plain-language summary

The goal of this observational study is to better understand real-world use of vimseltinib, treatment patterns, and health-related quality of life in participants treated with vimseltinib for TGCT. This study will collect data in an observational disease registry involving no intervention to the participants and will not influence standard medical care or impact treatment decisions for participants.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Diagnosis of TGCT according to medical records
. Prescribed vimseltinib per the approved label requirements. Participants are eligible if either (A) the decision to receive vimseltinib has been made but treatment has not yet been initiated or (B) the decision to receive vimseltinib has been made and participant has received first dose of prescribed vimseltinib less than 6 months prior to study enrollment
. Has provided informed consent and medical records release

Exclusion criteria

. Participant has received any other systemic agent for the treatment of TGCT during the 6 months prior to starting treatment with vimseltinib
. Participant has received the first dose of prescribed vimseltinib in the current treatment course more than 6 months before study enrollment

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Duration of Vimseltinib Treatment

Timeframe: Baseline up to 12 months

Time to Discontinuation of Vimseltinib

Timeframe: Baseline to Discontinuation (Estimated up to 12 months)

Trial details

NCT IDNCT07075471

SponsorDeciphera Pharmaceuticals, LLC

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2027-09

Contact for this trial

Clinical Team

888-724-3274 clinicaltrials@deciphera.com

View on ClinicalTrials.gov More Tenosynovial Giant Cell Tumor trials